BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37522565)

  • 1. Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer.
    Rizwi FA; Abubakar M; Puppala ER; Goyal A; Bhadrawamy CV; Naidu VGM; Roshan S; Tazneem B; Almalki WH; Subramaniyan V; Rawat S; Gupta G
    J Environ Pathol Toxicol Oncol; 2023; 42(4):15-29. PubMed ID: 37522565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
    Springuel L; Renauld JC; Knoops L
    Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK/STAT in leukemia: a clinical update.
    Liang D; Wang Q; Zhang W; Tang H; Song C; Yan Z; Liang Y; Wang H
    Mol Cancer; 2024 Jan; 23(1):25. PubMed ID: 38273387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK/STAT signaling pathway: from bench to clinic.
    Hu X; Li J; Fu M; Zhao X; Wang W
    Signal Transduct Target Ther; 2021 Nov; 6(1):402. PubMed ID: 34824210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
    Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
    Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
    Quintás-Cardama A; Verstovsek S
    Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
    Tzeng HT; Chyuan IT; Lai JH
    Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
    Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
    Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional targets of Drosophila JAK/STAT pathway signalling as effectors of haematopoietic tumour formation.
    Bina S; Wright VM; Fisher KH; Milo M; Zeidler MP
    EMBO Rep; 2010 Mar; 11(3):201-7. PubMed ID: 20168330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components.
    Chang WH; Lai AG
    Mol Med; 2019 Nov; 25(1):46. PubMed ID: 31684858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends.
    Zhang Y; Gao Z; Jiang F; Yan H; Yang B; He Q; Luo P; Xu Z; Yang X
    Biochem Pharmacol; 2023 Feb; 208():115382. PubMed ID: 36528067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
    Ferrajoli A; Faderl S; Ravandi F; Estrov Z
    Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human diseases caused by impaired signal transducer and activator of transcription and Janus kinase signaling.
    Chaimowitz NS; Forbes LR
    Curr Opin Pediatr; 2019 Dec; 31(6):843-850. PubMed ID: 31693596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
    Bose S; Banerjee S; Mondal A; Chakraborty U; Pumarol J; Croley CR; Bishayee A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32545187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
    Yang X; Tang Z; Zhang P; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
    Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
    J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
    Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
    Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.